FOXR1 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-10917
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the N-terminal region of human FOXR1 (NP_859072.1). Peptide sequence FLAFTTSHLPLAEQKLARYKLRIVKPPKLPLEKKPNPDKDGPDYEPNLWM
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
22 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for FOXR1 Antibody
Western Blot: FOXR1 Antibody [NBP3-10917]
Western Blot: FOXR1 Antibody [NBP3-10917] - Western blot analysis of FOXR1 in Pancreas tumor lysates. Antibody dilution at 1.0ug/mlApplications for FOXR1 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: FOXR1
Alternate Names
DLNB13, Forkhead box protein N5, forkhead box R1, forkhead box R1 variant 1, FOXN5forkhead box protein R1, MGC149486
Gene Symbol
FOXR1
Additional FOXR1 Products
Product Specific Notices for FOXR1 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...